Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 78

The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.

“Heads Up” for Creatine Supplementation and its Potential Applications for Brain Health and Function

Candow, Darren G., Forbes, Scott C., Ostojic, Sergej M., Prokopidis, Konstantinos, Stock, Matt S., Harmon, Kylie K., Faulkner, Paul·2023·Sports Medicine
DOI 10.1007/s40279-023-01870-9
Open this paper in CoChat — free account

Abstract

There is emerging interest regarding the potential beneficial effects of creatine supplementation on indices of brain health and function. Creatine supplementation can increase brain creatine stores, which may help explain some of the positive effects on measures of cognition and memory, especially in aging adults or during times of metabolic stress (i.e., sleep deprivation). Furthermore, creatine has shown promise for improving health outcome measures associated with muscular dystrophy, traumatic brain injury (including concussions in children), depression, and anxiety. However, whether any sex- or age-related differences exist in regard to creatine and indices of brain health and function is relatively unknown. The purpose of this narrative review is to: (1) provide an up-to-date summary and discussion of the current body of research focusing on creatine and indices of brain health and function and (2) discuss possible sex- and age-related differences in response to creatine supplementation on brain bioenergetics, measures of brain health and function, and neurological diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s40279-023-01870-9

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 122

  1. Persky A, Brazeau G. Clinical pharmacology of the dietary supplement creatine monohydrate. Pharmacol Rev. 2001;53:161–76.
  2. Delpino FM, Figueiredo LM, Forbes SC, Candow DG, Santos HO. Influence of age, sex, and type of exercise on the efficacy of creatine supplementation on lean body mass: a systematic review and meta-analysis of randomized clinical trials. Nutrition. 2022;103–104:111791. · DOI · Paper page
  3. Syrotuik D, Bell G. Acute creatine monohydrate supplementation: a descriptive physiological profile of responders vs nonresponders. J Strength Cond Res. 2004;18:610–7.
  4. Forbes SC, Cordingley DM, Cornish SM, Gualano B, Roschel H, Ostojic SM, et al. Effects of creatine supplementation on brain function and health. Nutrients. 2022;14:921. · DOI · Paper page
  5. Wallimann T, Tokarska-Schlattner M, Schlattner U. The creatine kinase system and pleiotropic effects of creatine. Amino Acid. 2011;40:1271. · DOI · Paper page
  6. Raichle ME, Gusnard DA. Appraising the brain’s energy budget. Proc Natl Acad Sci U S A. 2002;99:10237–9. · DOI · Paper page
  7. De Graaf RA. In vivo NMR spectroscopy: principles and techniques. 2018. Available from: https://www.wiley.com/en-us/In+Vivo+NMR+Spectroscopy%3A+Principles+and+Techniques%2C+3rd+Edition-p-9781119382515. Accessed 18 Dec 2022.
  8. Fons C, Campistol J. Creatine defects and central nervous system. Semin Pediatr Neurol. 2016;23:285–9. · DOI
  9. Ostojic SM. Low tissue creatine: a therapeutic target in clinical nutrition. Nutrients. 2022;14:1230. · DOI
  10. Braissant O, Bachmann C, Henry H. Expression and function of AGAT, GAMT and CT1 in the mammalian brain. Subcell Biochem. 2007;46:67–81. · DOI
  11. Ohtsuki S, Tachikawa M, Takanaga H, Shimizu H, Watanabe M, Hosoya KI, et al. The blood-brain barrier creatine transporter is a major pathway for supplying creatine to the brain. J Cereb Blood Flow Metab. 2002;22:1327–35. · DOI
  12. Yazigi Solis M, De Salles PV, Artioli GG, Roschel H, Otaduy MC, Gualano B. Brain creatine depletion in vegetarians? A cross-sectional 1H-magnetic resonance spectroscopy (1H-MRS) study. Br J Nutr. 2014;111:1272–4. · DOI
  13. Kondo DG, Forrest LN, Shi X, Sung Y-H, Hellem TL, Huber RS, et al. Creatine target engagement with brain bioenergetics: a dose-ranging phosphorus-31 magnetic resonance spectroscopy study of adolescent females with SSRI-resistant depression. Amino Acids. 2016;48:1941–54. · DOI · Paper page
  14. Fernandes-Pires G, Braissant O. Current and potential new treatment strategies for creatine deficiency syndromes. Mol Genet Metab. 2022;135:15–26. · DOI · Paper page
  15. Braissant O, Henry H. AGAT, GAMT and SLC6A8 distribution in the central nervous system, in relation to creatine deficiency syndromes: a review. J Inherit Metab Dis. 2008;31:230–9. · DOI
  16. Christie DL. Functional insights into the creatine transporter. Subcell Biochem. 2007;46:99–118. · DOI
  17. Snow RJ, Murphy RM. Creatine and the creatine transporter: a review. Mol Cell Biochem. 2001;224:169–81. · DOI
  18. Ostojic SM. Modulation of CT1 function: from klotho protein to ammonia and beyond. Front Nutr. 2021;8:660021. · DOI
  19. Stead LM, Au KP, Jacobs RL, Brosnan ME, Brosnan JT. Methylation demand and homocysteine metabolism: effects of dietary provision of creatine and guanidinoacetate. Am J Physiol Endocrinol Metab. 2001;281:E1100. · DOI
  20. Ostojic SM, Stojanovic M, Drid P, Hoffman JR, Sekulic D, Zenic N. Supplementation with guanidinoacetic acid in women with chronic fatigue syndrome. Nutrients. 2016;8:72. · DOI
  21. Bender A, Samtleben W, Elstner M, Klopstock T. Long-term creatine supplementation is safe in aged patients with Parkinson disease. Nutr Res. 2008;28:172–8. · DOI · Paper page
  22. Snow WM, Cadonic C, Cortes-Perez C, Adlimoghaddam A, Roy Chowdhury SK, Thomson E, et al. Sex-specific effects of chronic creatine supplementation on hippocampal-mediated spatial cognition in the 3xTg mouse model of Alzheimer’s disease. Nutrients. 2020;12:3589. · DOI
  23. Snow WM, Cadonic C, Cortes-Perez C, Roy Chowdhury SK, Djordjevic J, Thomson E, et al. Chronic dietary creatine enhances hippocampal-dependent spatial memory, bioenergetics, and levels of plasticity-related proteins associated with NF-κB. Learn Mem. 2018;25:54–66. · DOI · Paper page
  24. Kaltschmidt B, Ndiaye D, Korte M, Pothion S, Arbibe L, Prüllage M, et al. NF-kappaB regulates spatial memory formation and synaptic plasticity through protein kinase A/CREB signaling. Mol Cell Biol. 2006;26:2936–46. · DOI
  25. Mao X, Kelty TJ, Kerr NR, Childs TE, Roberts MD, Booth FW. Creatine supplementation upregulates mTORC1 signaling and markers of synaptic plasticity in the dentate gyrus while ameliorating LPS-induced cognitive impairment in female rats. Nutrients. 2021;13:2758. · DOI
  26. AliMohammadi M, Eshraghian M, Zarindast MR, Aliaghaei A, Pishva H. Effects of creatine supplementation on learning, memory retrieval, and apoptosis in an experimental animal model of Alzheimer disease. Med J Islam Repub Iran. 2015;29:273.
  27. Ramesh V, Nair D, Zhang SXL, Hakim F, Kaushal N, Kayali F, et al. Disrupted sleep without sleep curtailment induces sleepiness and cognitive dysfunction via the tumor necrosis factor-α pathway. J Neuroinflamm. 2012;9:1–15. · DOI
  28. D’Rozario AL, Bartlett DJ, Wong KKH, Sach T, Yang Q, Grunstein RR, et al. Brain bioenergetics during resting wakefulness are related to neurobehavioral deficits in severe obstructive sleep apnea: a 31P magnetic resonance spectroscopy study. Sleep. 2018;41:zsy117. · DOI
  29. Dworak M, Kim T, Mccarley RW, Basheer R. Creatine supplementation reduces sleep need and homeostatic sleep pressure in rats. J Sleep Res. 2017;26:377–85. · DOI
  30. McMorris T, Mielcarz G, Harris RC, Swain JP, Howard A. Creatine supplementation and cognitive performance in elderly individuals. Neuropsychol Dev Cogn B Aging Neuropsychol Cogn. 2007;14:517–28. · DOI · Paper page
  31. Merege-Filho CAA, Otaduy MCG, De Sá-Pinto AL, De Oliveira MO, De Souza GL, Hayashi APT, et al. Does brain creatine content rely on exogenous creatine in healthy youth? A proof-of-principle study. Appl Physiol Nutr Metab. 2017;42:128–34. · DOI · Paper page
  32. Turner CE, Byblow WD, Gant N. Creatine supplementation enhances corticomotor excitability and cognitive performance during oxygen deprivation. J Neurosci. 2015;35:1773. · DOI · Paper page
  33. Watanabe A, Kato N, Kato T. Effects of creatine on mental fatigue and cerebral hemoglobin oxygenation. Neurosci Res. 2002;42:279–85. · DOI · Paper page
  34. Ainsley Dean PJ, Arikan G, Opitz B, Sterr A. Potential for use of creatine supplementation following mild traumatic brain injury. Concussion. 2017;2:CNC34. · DOI · Paper page
  35. Vedung F, Fahlström M, Wall A, Antoni G, Lubberink M, Johansson J, et al. Chronic cerebral blood flow alterations in traumatic brain injury and sports-related concussions. Brain Inj. 2022;36:948–60. · DOI
  36. Sullivan P, Geiger J, Mattson M, Scheff S. Dietary supplement creatine protects against traumatic brain injury. Ann Neurol. 2000;48:723–9. · DOI
  37. Scheff SW, Dhillon HS. Creatine-enhanced diet alters levels of lactate and free fatty acids after experimental brain injury. Neurochem Res. 2004;29:469–79. · DOI
  38. Dong XX, Wang Y, Qin ZH. Molecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseases. Acta Pharmacol Sin. 2009;30:379. · DOI · Paper page
  39. Masse I, Moquin L, Bouchard C, Gratton A, De Beaumont L. Efficacy of prophylactic versus therapeutic administration of the NMDA receptor antagonist MK-801 on the acute neurochemical response to a concussion in a rat model combining force and rotation. J Neurosurg. 2021;136:1–10.
  40. Genius J, Geiger J, Bender A, Möller HJ, Klopstock T, Rujescu D. Creatine protects against excitoxicity in an in vitro model of neurodegeneration. PLoS ONE. 2012;7: e30554. · DOI
  41. Sakellaris G, Nasis G, Kotsiou M, Tamiolaki M, Charissis G, Evangeliou A. Prevention of traumatic headache, dizziness and fatigue with creatine administration: a pilot study. Acta Paediatr. 2008;97:34. · DOI
  42. Chaychi S, Valera E, Tartaglia MC. Sex and gender differences in mild traumatic brain injury/concussion. Int Rev Neurobiol. 2022;164:349–75. · DOI
  43. Ravina BM, Fagan SC, Hart RG, Hovinga CA, Murphy DD, Dawson TM, et al. Neuroprotective agents for clinical trials in Parkinson’s disease: a systematic assessment. Neurology. 2003;60:1234–40. · DOI · Paper page
  44. Ostojic SM. Creatine and multiple sclerosis. Nutr Neurosci. 2022;25:912–9. · DOI
  45. Soria Lopez JA, González HM, Léger GC. Alzheimer’s disease. Handb Clin Neurol. 2019;167:231–55. · DOI · Paper page
  46. Rijpma A, van der Graaf M, Meulenbroek O, Olde Rikkert MGM, Heerschap A. Altered brain high-energy phosphate metabolism in mild Alzheimer’s disease: a 3-dimensional 31P MR spectroscopic imaging study. NeuroImage Clin. 2018;18:254–61. · DOI
  47. Pettegrew JW, Panchalingam K, Klunk WE, McClure RJ, Muenz LR. Alterations of cerebral metabolism in probable Alzheimer’s disease: a preliminary study. Neurobiol Aging. 1994;15:117–32. · DOI
  48. Aksenov MY, Aksenova MV, Payne RM, Smith CD, Markesbery WR, Carney JM. The expression of creatine kinase isoenzymes in neocortex of patients with neurodegenerative disorders: Alzheimer’s and Pick’s disease. Exp Neurol. 1997;146:458–65. · DOI
  49. Laakso MP, Hiltunen Y, Könönen M, Kivipelto M, Koivisto A, Hallikainen M, et al. Decreased brain creatine levels in elderly apolipoprotein E ε4 carriers. J Neural Transm. 2003;110:267–75. · DOI
  50. Alimohammadi-Kamalabadi M, Eshraghian M, Zarindast M, Aliaghaei A, Pishva H. Effect of creatine supplementation on cognitive performance and apoptosis in a rat model of amyloid-beta-induced Alzheimer’s disease. Iran J Basic Med Sci. 2016;19:1159–65.
  51. Sagna A, Gallo JJ, Pontone GM. Systematic review of factors associated with depression and anxiety disorders among older adults with Parkinson’s disease. Parkinsonism Relat Disord. 2014;20:708–15. · DOI
  52. Matthews RT, Ferrante RJ, Klivenyi P, Yang L, Klein AM, Mueller G, et al. Creatine and cyclocreatine attenuate MPTP neurotoxicity. Exp Neurol. 1999;157:142–9. · DOI · Paper page
  53. Klein AM, Ferrante RJ. The neuroprotective role of creatine. Subcell Biochem. 2007;46:205–43. · DOI
  54. Bender A, Koch W, Elstner M, Schombacher Y, Bender J, Moeschl M, et al. Creatine supplementation in Parkinson disease: a placebo-controlled randomized pilot trial. Neurology. 2006;67:1262–4. · DOI
  55. Li Z, Wang P, Yu Z, Cong Y, Sun H, Zhang J, et al. The effect of creatine and coenzyme q10 combination therapy on mild cognitive impairment in Parkinson’s disease. Eur Neurol. 2015;73:205–11. · DOI
  56. Ravina B, Kieburtz K, Tilley B, Shannon K, Tanner C, Frederick Wooten G, et al. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology. 2006;66:664–71. · DOI · Paper page
  57. Kieburtz K, Tilley B, Ravina B, Galpern WR, Shannon K, Tanner C, et al. A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month results. Clin Neuropharmacol. 2008;31:141–50. · DOI
  58. Kieburtz K, Tilley BC, Elm JJ, Babcock D, Hauser R, Ross GW, et al. Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial. JAMA. 2015;313:584–93. · DOI · Paper page
  59. Alonso A, Hernán MA. Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurology. 2008;71:129–35. · DOI · Paper page
  60. Goldenberg MM. Multiple sclerosis review. Pharm Ther. 2012;37:175.
  61. Dalgas U, Langeskov-Christensen M, Stenager E, Riemenschneider M, Hvid LG. Exercise as medicine in multiple sclerosis: time for a paradigm shift: preventive, symptomatic, and disease-modifying aspects and perspectives. Curr Neurol Neurosci Rep. 2019;19:1–12. · DOI · Paper page
  62. Taul-Madsen L, Connolly L, Dennett R, Freeman J, Dalgas U, Hvid LG. Is aerobic or resistance training the most effective exercise modality for improving lower extremity physical function and perceived fatigue in people with multiple sclerosis? A systematic review and meta-analysis. Arch Phys Med Rehabil. 2021;102:2032–48. · DOI
  63. Beer M, Sandstede J, Weilbach F, Spindler M, Buchner S, Krug A, et al. Cardiac metabolism and function in patients with multiple sclerosis: a combined 31P-MR-spectroscopy and MRI study. Rofo. 2001;173:399–404. · DOI
  64. Arnold DL, Riess GT, Matthews PM, Francis GS, Collins DL, Wolfson C, et al. Use of proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis. Ann Neurol. 1994;36:76–82. · DOI
  65. Lynch J, Peeling J, Auty A, Sutherland G. Nuclear magnetic resonance study of cerebrospinal fluid from patients with multiple sclerosis. Can J Neurol Sci. 1993;20:194–8. · DOI
  66. Lambert CP, Archer RL, Carrithers JA, Fink WJ, Evans WJ, Trappe TA. Influence of creatine monohydrate ingestion on muscle metabolites and intense exercise capacity in individuals with multiple sclerosis. Arch Phys Med Rehabil. 2003;84:1206–10. · DOI
  67. Malin SK, Cotugna N, Fang CS. Effect of creatine supplementation on muscle capacity in individuals with multiple sclerosis. J Diet Suppl. 2008;5:20–32. · DOI
  68. Zucchi E, Bonetto V, Sorarù G, Martinelli I, Parchi P, Liguori R, et al. Neurofilaments in motor neuron disorders: towards promising diagnostic and prognostic biomarkers. Mol Neurodegener. 2020;15:1–20. · DOI
  69. Gittings LM, Sattler R. Recent advances in understanding amyotrophic lateral sclerosis and emerging therapies. Fac Rev. 2020;9:12. · DOI
  70. Tarnopolsky MA, Beal MF. Potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders. Ann Neurol. 2001;49:561–74. · DOI · Paper page
  71. Wyss M, Schulze A. Health implications of creatine: can oral creatine supplementation protect against neurological and atherosclerotic disease? Neuroscience. 2002;112:243–60. · DOI · Paper page
  72. Beal MF. Neuroprotective effects of creatine. Amino Acids. 2011;40:1305–13. · DOI
  73. Klopstock T, Elstner M, Bender A. Creatine in mouse models of neurodegeneration and aging. Amino Acids. 2011;40:1297–303. · DOI
  74. Hervias I, Beal MF, Manfredi G. Mitochondrial dysfunction and amyotrophic lateral sclerosis. Muscle Nerve. 2006;33:598–608. · DOI
  75. Klivenyi P, Kiaei M, Gardian G, Calingasan NY, Beal MF. Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurochem. 2004;88:576–82. · DOI
  76. Klivenyi P, Ferrante RJ, Matthews RT, Bogdanov MB, Klein AM, Andreassen OA, et al. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat Med. 1999;5:347–50. · DOI · Paper page
  77. Andreassen OA, Jenkins BG, Dedeoglu A, Ferrante KL, Bogdanov MB, Kaddurah-Daouk R, et al. Increases in cortical glutamate concentrations in transgenic amyotrophic lateral sclerosis mice are attenuated by creatine supplementation. J Neurochem. 2001;77:383–90. · DOI
  78. Derave W, Van Den Bosch L, Lemmens G, Eijnde BO, Robberecht W, Hespel P. Skeletal muscle properties in a transgenic mouse model for amyotrophic lateral sclerosis: effects of creatine treatment. Neurobiol Dis. 2003;13:264–72. · DOI
  79. Mazzini L, Balzarini C, Colombo R, Mora G, Pastore I, De Ambrogio R, et al. Effects of creatine supplementation on exercise performance and muscular strength in amyotrophic lateral sclerosis: preliminary results. J Neurol Sci. 2001;191:139–44. · DOI
  80. Groeneveld GJ, Veldink JH, Van der Tweel I, Kalmijn S, Beijer C, De Visser M, et al. A randomized sequential trial of creatine in amyotrophic lateral sclerosis. Ann Neurol. 2003;53:437–45. · DOI · Paper page
  81. Rosenfeld J, King RM, Jackson CE, Bedlack RS, Barohn RJ, Dick A, et al. Creatine monohydrate in ALS: effects on strength, fatigue, respiratory status and ALSFRS. Amyotroph Lateral Scler. 2008;9:266–72. · DOI
  82. Shefner JM, Cudkowicz ME, Schoenfeld D, Conrad T, Taft J, Chilton M, et al. A clinical trial of creatine in ALS. Neurology. 2004;63:1656–61. · DOI · Paper page
  83. Drory VE, Gross D. No effect of creatine on respiratory distress in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2002;3:43–6. · DOI
  84. Tarnopolsky M, Parise G. Direct measurement of high-energy phosphate compounds in patients with neuromuscular disease. Muscle Nerve. 1999;22:1228–33. · DOI
  85. Fitch CD, Moody LG. Creatine metabolism in skeletal muscle. V. An intracellular abnormality of creatine trapping in dystrophic muscle. Proc Soc Exp Biol Med. 1969;132:219–22. · DOI
  86. Passamano L, Taglia A, Palladino A, Viggiano E, D’Ambrosio P, Scutifero M, et al. Improvement of survival in Duchenne muscular dystrophy: retrospective analysis of 835 patients. Acta Myol. 2012;31:125.
  87. Passaquin AC, Renard M, Kay L, Challet C, Mokhtarian A, Wallimann T, et al. Creatine supplementation reduces skeletal muscle degeneration and enhances mitochondrial function in mdx mice. Neuromuscul Disord. 2002;12:174–82. · DOI · Paper page
  88. Ogborn DI, Smith KJ, Crane JD, Safdar A, Hettinga BP, Tupler R, et al. Effects of creatine and exercise on skeletal muscle of FRG1-transgenic mice. Can J Neurol Sci. 2012;39:225–31. · DOI · Paper page
  89. Davidson ZE, Hughes I, Ryan MM, Kornberg AJ, Cairns AG, Jones K, et al. Effect of a multicomponent nutritional supplement on functional outcomes for Duchenne muscular dystrophy: a randomized controlled trial. Clin Nutr. 2021;40:4702–11. · DOI
  90. Tarnopolsky M, Mahoney D, Thompson T, Naylor H, Doherty TJ. Creatine monohydrate supplementation does not increase muscle strength, lean body mass, or muscle phosphocreatine in patients with myotonic dystrophy type 1. Muscle Nerve. 2004;29:51–8. · DOI · Paper page
  91. Walter MC, Reilich P, Lochmüller H, Kohnen R, Schlotter B, Hautmann H, et al. Creatine monohydrate in myotonic dystrophy: a double-blind, placebo-controlled clinical study. J Neurol. 2002;249:1717–22. · DOI · Paper page
  92. Schneider-Gold C, Beck M, Wessig C, George A, Kele H, Reiners K, et al. Creatine monohydrate in DM2/PROMM: a double-blind placebo-controlled clinical study. Proximal myotonic myopathy. Neurology. 2003;60:500–2. · DOI · Paper page
  93. McCorquodale D, Pucillo EM, Johnson NE. Management of Charcot–Marie–Tooth disease: improving long-term care with a multidisciplinary approach. J Multidiscip Healthc. 2016;9:7–19.
  94. Doherty TJ, Lougheed K, Markez J, Tarnopolsky MA. Creatine monohydrate does not increase strength in patients with hereditary neuropathy. Neurology. 2001;57:559–60. · DOI
  95. Chetlin RD, Gutmann L, Tarnopolsky MA, Ullrich IH, Yeater RA. Resistance training exercise and creatine in patients with Charcot-Marie-Tooth disease. Muscle Nerve. 2004;30:69–76. · DOI · Paper page
  96. Smith CA, Chetlin RD, Gutmann L, Yeater RA, Alway SE. Effects of exercise and creatine on myosin heavy chain isoform composition in patients with Charcot–Marie–Tooth disease. Muscle Nerve. 2006;34:586–94. · DOI · Paper page
  97. Jung WY, Jang SH, Kim SG, Jae YM, Kong BG, Kim HC, et al. Times to discontinue antidepressants over 6 months in patients with major depressive disorder. Psychiatry Investig. 2016;13:440–6. · DOI
  98. Moncrieff J, Cooper RE, Stockmann T, Amendola S, Hengartner MP, Horowitz MA. The serotonin theory of depression: a systematic umbrella review of the evidence. Mol Psychiatry. 2022. https://doi.org/10.1038/s41380-022-01661-0. · DOI · Paper page
  99. Parsey RV, Oquendo MA, Ogden RT, Olvet DM, Simpson N, Huang YY, et al. Altered serotonin 1A binding in major depression: a [carbonyl-C-11]WAY100635 positron emission tomography study. Biol Psychiatry. 2006;59:106–13. · DOI · Paper page
  100. Persson J, Wall A, Weis J, Gingnell M, Antoni G, Lubberink M, et al. Inhibitory and excitatory neurotransmitter systems in depressed and healthy: a positron emission tomography and magnetic resonance spectroscopy study. Psychiatry Res Neuroimaging. 2021;315: 111327. · DOI
  101. Kumar A, Thomas A, Lavretsky H, Yue K, Huda A, Curran J, et al. Frontal white matter biochemical abnormalities in late-life major depression detected with proton magnetic resonance spectroscopy. Am J Psychiatry. 2002;159:630–6. · DOI
  102. Li BSY, Wang H, Gonen O. Metabolite ratios to assumed stable creatine level may confound the quantification of proton brain MR spectroscopy. Magn Reson Imaging. 2003;21:923–8. · DOI
  103. Chang L, Mehringer CM, Ernst T, Melchor R, Myers H, Forney D, et al. Neurochemical alterations in asymptomatic abstinent cocaine users: a proton magnetic resonance spectroscopy study. Biol Psychiatry. 1997;42:1105–14. · DOI
  104. Faulkner P, Lucini Paioni S, Kozhuharova P, Orlov N, Lythgoe DJ, Daniju Y, et al. Daily and intermittent smoking are associated with low prefrontal volume and low concentrations of prefrontal glutamate, creatine, myo-inositol, and N-acetylaspartate. Addict Biol. 2021;26:e12986. · DOI
  105. Prescot AP, Locatelli AE, Renshaw PF, Yurgelun-Todd DA. Neurochemical alterations in adolescent chronic marijuana smokers: a proton MRS study. Neuroimage. 2011;57:69–75. · DOI
  106. Öngür D, Prescot AP, Jensen JE, Cohen BM, Renshaw PF. Creatine abnormalities in schizophrenia and bipolar disorder. Psychiatry Res. 2009;172:44–8. · DOI
  107. Auer DP, Pütz B, Kraft E, Lipinski B, Schill J, Holsboer F. Reduced glutamate in the anterior cingulate cortex in depression: an in vivo proton magnetic resonance spectroscopy study. Biol Psychiatr. 2000;47:305–13. · DOI · Paper page
  108. Mirza Y, O’Neill J, Smith EA, Russell A, Smith JM, Banerjee SP, et al. Increased medial thalamic creatine-phosphocreatine found by proton magnetic resonance spectroscopy in children with obsessive-compulsive disorder versus major depression and healthy controls. J Child Neurol. 2006;21:106–11. · DOI
  109. Faulkner P, Paioni SL, Kozhuharova P, Orlov N, Lythgoe DJ, Daniju Y, et al. Relationship between depression, prefrontal creatine and grey matter volume. J Psychopharmacol. 2021;35:1464–72. · DOI
  110. Yue Q, Liu M, Nie X, Wu Q, Li J, Zhang W, et al. Quantitative 3.0T MR spectroscopy reveals decreased creatine concentration in the dorsolateral prefrontal cortex of patients with social anxiety disorder. PLoS ONE. 2012;7:e48105. · DOI
  111. Lyoo IK, Yoon S, Kim TS, Hwang J, Kim JE, Won W, et al. A randomized, double-blind placebo-controlled trial of oral creatine monohydrate augmentation for enhanced response to a selective serotonin reuptake inhibitor in women with major depressive disorder. Am J Psychiatry. 2012;169:937–45. · DOI · Paper page
  112. Nemets B, Levine J. A pilot dose-finding clinical trial of creatine monohydrate augmentation to SSRIs/SNRIs/NASA antidepressant treatment in major depression. Int Clin Psychopharmacol. 2013;28:127–33. · DOI
  113. Braissant O. Creatine and guanidinoacetate transport at blood-brain and blood-cerebrospinal fluid barriers. J Inherit Metab Dis. 2012;35:655–64. · DOI · Paper page
  114. van de Kamp JM, Pouwels PJW, Aarsen FK, ten Hoopen LW, Knol DL, de Klerk JB, et al. Long-term follow-up and treatment in nine boys with X-linked creatine transporter defect. J Inherit Metab Dis. 2012;35:149. · DOI · Paper page
  115. Pazini FL, Cunha MP, Rosa JM, Colla ARS, Lieberknecht V, Oliveira Á, et al. Creatine, similar to ketamine, counteracts depressive-like behavior induced by corticosterone via PI3K/Akt/mTOR pathway. Mol Neurobiol. 2016;53:6818–34. · DOI
  116. Assis LC, Rezin GT, Comim CM, Valvassori SS, Jeremias IC, Zugno AI, et al. Effect of acute administration of ketamine and imipramine on creatine kinase activity in the brain of rats. Rev Bras Psiquiatr. 2009;31:247–52. · DOI
  117. Mirowsky J, Ross CE. Age and depression. J Health Soc Behav. 1992;33:187–205. · DOI · Paper page
  118. Lind A, Boraxbekk CJ, Petersen ET, Paulson OB, Siebner HR, Marsman A. Regional myo-inositol, creatine, and choline levels are higher at older age and scale negatively with visuospatial working memory: a cross-sectional proton MR spectroscopy study at 7 Tesla on normal cognitive ageing. J Neurosci. 2020;40:8149–59. · DOI
  119. Brown MS, Singel D, Hepburn S, Rojas DC. Increased glutamate concentration in the auditory cortex of persons with autism and first-degree relatives: a (1)H-MRS study. Autism Res. 2013;6:1–10. · DOI
  120. Nagae-Poetscher LM, Bonekamp D, Barker PB, Brant LJ, Kaufmann WE, Horská A. Asymmetry and gender effect in functionally lateralized cortical regions: a proton MRS imaging study. J Magn Reson Imaging. 2004;19:27–33. · DOI
  121. Pouwels PJW, Frahm J. Regional metabolite concentrations in human brain as determined by quantitative localized proton MRS. Magn Reson Med. 1998;39:53–60. · DOI · Paper page
  122. Tayoshi S, Sumitani S, Taniguchi K, Shibuya-Tayoshi S, Numata S, Iga J, et al. Metabolite changes and gender differences in schizophrenia using 3-Tesla proton magnetic resonance spectroscopy (1H-MRS). Schizophr Res. 2009;108:69–77. · DOI

Cited by

See all 78

Metadata

Authors
Candow, D. G., Forbes, S. C., Ostojic, S. M., Prokopidis, K., Stock, M. S., Harmon, K. K., & Faulkner, P.
Venue
Sports Medicine
Publisher
Springer Science and Business Media LLC
Published
2023-06-27
Volume
53
Issue
S1
Pages
49-65
ISSN
  • 0112-1642
  • 1179-2035
DOI
10.1007/s40279-023-01870-9
Cited by
78
References
43
Language
en
Update notices
correction (2023-07-10)
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.